The Quantellect read.As of Nov 19, 2026, 4 active firms cover X4 Pharmaceuticals Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $10.00 to $12.00, so the covering firms are broadly aligned. The average target of $11.25 sits 279% above the current $2.97. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.19 next quarter toward $-0.78 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$11.25
+278.8% upside
Average target across 4 active firms as of Nov 19, 2026 vs $2.97 current
Highest Target$12.00
Average Target$11.25
Lowest Target$10.00
Detailed analyst forecasts for XFOR
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate XFOR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
XFOR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.19 – $-0.19 · 2 analysts · +19% YoY
Next period, 2 analysts expect X4 Pharmaceuticals Inc to earn $-0.19 a share (range $-0.19 – $-0.19), versus $-0.16 a year earlier. Full-year consensus is $-0.64, growing to $-0.78 the year after.
REVENUE · NEXT QUARTER
$2.2M
Range $2.0M – $2.4M · 2 analysts · -19% YoY
Revenue is expected to reach $2.2M (range $2.0M – $2.4M), -18.8% year-over-year. Full-year consensus is $17.3M, rising to $12.4M next year.
Top analysts covering X4 Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on XFOR.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$12.00+304.0% to target
Overall win rate
53%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
$14.00+371.4% to target
Overall win rate
38%
+ Follow
#3
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$5.00+68.4% to target
Overall win rate
38%
+ Follow
#4
Thomas Smith
Leerink Partners · Rank #412
Buy
$12.00+304.0% to target
Overall win rate
41%
+ Follow
#5
SW
Stephen Willey
Stifel · Rank #474
Buy
$9.00+203.0% to target
Overall win rate
29%
+ Follow
XFOR stock forecast FAQ
What is XFOR's average 12-month price target?+
The 4 active firms with a live target average $11.25 for X4 Pharmaceuticals Inc over the next 12 months, ranging from a $12.00 high to a $10.00 low, as of Nov 19, 2026.
Is XFOR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for XFOR?+
The Street-high target is $12.00 (Leerink Partners), and the Street-low is $10.00 (Stifel). The average of all 4 active-firm targets is $11.25.
How many active Wall Street firms cover XFOR?+
4 active firms have a recognized rating on X4 Pharmaceuticals Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering XFOR?+
Among analysts who currently cover XFOR, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $12.00 target.
What is X4 Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.19 – $-0.19) across 2 analysts. Full-year EPS is projected at $-0.64, rising to $-0.78 the following year.
How much revenue is X4 Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $2.2M (range $2.0M – $2.4M). Full-year revenue is projected at $17.3M, growing to $12.4M next year.
Have analysts been upgrading or downgrading XFOR lately?+
As of Nov 19, 2026, 4 of 4 active firms rate XFOR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their XFOR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.